Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04778306
Other study ID # SBUADYBTRH
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2010
Est. completion date December 31, 2019

Study information

Verified date February 2021
Source Saglik Bilimleri Universitesi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: The investigators aimed to compare the oncological results of patients with early stage laryngeal squamous cell carcinoma (LSCC) treated with Transoral Laryngeal Surgery (TOLS) and Radiotheraphy (RT). Methods: The patients were divided into two groups as TOLS (Group 1) and RT (Group 2) according to the treatment method. Both groups were compared with each other in terms of local recurrence, regional recurrence, distant metastasis, 3 and 5-year overall survival, disease-free survival, disease-specific survival and laryngectomy-free survival rates. Survival analyses was made by Kaplan Meier product limit estimation. A p-value of less than 0.05 was considered as statistically significant.


Description:

Laryngeal cancers are one of the most common head and neck cancers (HNC). According to the 2018 cancer statistics, the estimated number of new laryngeal cancer cases annually is 177.000, and approximately half of these cases died due to the laryngeal cancer. While the most common HNC in the world is oral cavity cancer, in Turkey the most common HNC is laryngeal cancer. In Turkey, laryngeal cancers are showed 6.6/ 100.000 in men, 0.5/ 100.000 in women, and it ranked eighth in cancer deaths in men. Every year in Turkey, more than 3500 cases of new laryngeal cancer are expected, and its incidence has increased significantly in the last ten years. In the main treatment of early stage laryngeal cancers, surgery (transoral laryngeal surgery (TOLS) - open partial laryngeal surgery (OPLS)) and radiotherapy (RT) are used. Although the oncological results of all of three treatment strategies are similar, TOLS performed with laser is preferred mostly because of short hospital stay, low cost, good functional result, low morbidity and mortality. There are quite different studies in the literature on whether surgical and non-surgical treatment methods used in the treatment of early stage laryngeal cancers are superior to each other in terms of oncological results. In a randomized controlled study with a large patient series comparing surgery and radiotherapy, 5-year overall survival (OS) in T1 tumors (91.7% in the RT group, 100% in the surgery group) and in T2 tumors (88.8% in the RT group, 97.4% in the surgery group) was similar. 5-year disease-free survival (DFS) in T2 tumors (60.1% in RT group, 78.7% in surgery group) was higher in favor of surgery. Studies comparing TOLS and radiotheraphy in the treatment of early stage laryngeal cancer within the last 20 years have reported comparable oncologic outcomes; two recent meta-analyses have reported better overall survival after TOLS than radiotheraphy, despite being able to show any difference in local control. In this study, we aimed to compare the effects of TOLS and RT on local control, regional control, overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS) and larynjectomy-free survival (LFS) in early stage laryngeal cancers in our own series of patients with high patient volume and long follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 261
Est. completion date December 31, 2019
Est. primary completion date December 31, 2019
Accepts healthy volunteers No
Gender All
Age group 33 Years to 83 Years
Eligibility Inclusion Criteria: - Early stage laryngeal cancer (Tis-1-2N0M0) - >18 years old. Exclusion Criteria: - <18 years old - History of another malignant disease - Incomplete data - Non-squamous cell carcinoma - No follow-up.

Study Design


Intervention

Procedure:
Transoral Laser Surgery
Remove of the laryngeal tumour via diode laser

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Saglik Bilimleri Universitesi

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival Overall survival at least 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Completed NCT03292341 - Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients. N/A
Completed NCT03653039 - Comparison Between a Standard Tube and the Ultra-thin Tritube for Intubation of the Trachea and for Maintaining Access to the Trachea After Anaesthesia, in Patients With an Expected Difficult Direct Laryngoscopy N/A
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Completed NCT01700647 - Breath Testing in Early and Late Larynx Cancer N/A
Completed NCT00169247 - Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Phase 2
Completed NCT00600223 - Functional Voice and Speech Outcomes Following Surgical Voice Restorations: A Comparison of Pharyngeal Construction Approaches N/A
Recruiting NCT03759431 - Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer Phase 2
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT04057209 - VoiceS: Voice Quality After Transoral CO2-Laser Surgery Versus Single Vocal Cord Irradiation for Larynx Cancer N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06086119 - Quality of Life and Voice Perception in Patients Laryngoctomized Phonatory Wearers
Suspended NCT04368702 - CONFIRM: Magnetic Resonance Guided Radiation Therapy N/A
Completed NCT05217147 - An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma
Active, not recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Completed NCT00158652 - Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Phase 3
Terminated NCT03479463 - Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy
Completed NCT03096808 - Adaptive Radiotherapy for Head and Neck Cancer Phase 2
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1